Displaying drugs 651 - 675 of 11575 in total
Acetohexamide
A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.
Approved
Investigational
Withdrawn
Matched Description: … A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. …
Insulin aspart
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the...
Approved
Matched Description: … build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening ... Insulin aspart is a recombinant, biosynthetic, fast-acting insulin analogue. ... Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type …
Abaloparatide
Abaloparatide is an N-terminal analog of parathyroid hormone-related protein (PTHrP) and an agonist at the parathyroid hormone type 1 (PTH1) receptor. It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and human PTHrP 1-34. Abaloparatide and PTHrP share the first 21 amino acids...
Approved
Investigational
Matched Description: … [L740] It is a synthetic 34 amino acid peptide with 41% homology to human parathyroid hormone 1-34 and …
Bempedoic acid
High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease. About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are...
Approved
Investigational
Matched Description: … High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. ... Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a ... A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased …
Clodronic acid
Clodronic acid is a first generation bisphosphonate similar to etidronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. clodronate’s use has decreased over the years in favor of the third generation, nitrogen containing bisphosphonate zoledronic acid, ibandronic acid,...
Approved
Investigational
Vet approved
Matched Description: … Clodronic acid is a first generation bisphosphonate similar to [etidronic acid] and [tiludronic acid] ... [A203111] These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification …
Mefenamic acid
A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Approved
Matched Description: … A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties …
Etacrynic acid
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop...
Approved
Investigational
Matched Description: … This compound has been classified as a loop or high ceiling diuretic. ... A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of …
Benzyl alcohol
Approved
Halazepam
Halazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by Schering, its manufacturer, in 2009.[L6226, L6229]
Approved
Illicit
Withdrawn
Matched Description: … Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle …
Quinethazone
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. …
Influenza B virus B/Austria/1359417/2021 live (attenuated) antigen
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses. These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in...
Approved
Matched Description: … , or inactivated, through exposure to heat or chemicals such as formaldehyde. ... A seasonally-specific component of the influenza vaccine. ... The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection …
Beractant
Beractant is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of phospholipids, neutral lipids, fatty acids, and surfactant-associated proteins such as SP-B and SP-C. The...
Approved
Matched Description: … It is suspended in 0.9% sodium chloride solution, and heat-sterilized. ... Beractant is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in ... Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains …
Celiprolol
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 ... In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications ... of a rare inherited disease called vascular Ehlers–Danlos syndrome. …
Ledipasvir
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Description: … Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat ... HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 ... It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a …
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Cipaglucosidase alfa
Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by a deficiency in GAA. Other types of enzyme replacement therapy for the treatment of Pompe disease include alglucosidase alfa and avalglucosidase alfa. Cipaglucosidase...
Approved
Investigational
Matched Description: … a deficiency in GAA. ... Compared to alglucosidase alfa, cipaglucosidase alfa has a higher M6P content. ... Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated …
Vemurafenib
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Description: … Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E ... After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Drotrecogin alfa
Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated...
Approved
Investigational
Withdrawn
Matched Description: … a light chain linked by a disulfide bond. ... It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and ... Drotrecogin alfa was withdrawn from the market after a major study indicated that it was not effective …
Nomifensine
Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. The approved application holder removed Merital capsules from the market on January 23, 1986. FDA published a notice of its determination that Merital capsules were removed from the market for safety reasons (see the Federal...
Approved
Withdrawn
Matched Description: … FDA published a notice of its determination that Merital capsules were removed from the market for safety …
Lidoflazine
Approved
Experimental
Agalsidase beta
Agalsidase beta is a recombinant human α-galactosidase A similar to agalsidase alfa. While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.[A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa,...
Approved
Investigational
Matched Description: … Agalsidase beta is a recombinant human α-galactosidase A similar to [agalsidase alfa]. ... While patients generally do not experience a clinically significant difference in outcomes between the ... A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a …
Flufenamic acid
An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
Approved
Tolfenamic acid
Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. In the US, it presents a Status class I by the...
Approved
Investigational
Matched Description: … [L1292] In the US, it presents a Status class I by the FDA. ... It is used in the UK as a treatment for migraine under the name of Clotam. ... Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory …
Poa annua pollen
Poa annua pollen is the pollen of the Poa annua plant. Poa annua pollen is mainly used in allergenic testing.
Approved
Displaying drugs 651 - 675 of 11575 in total